Skip to content
PeptideAgent

Dulaglutide regulatory status

Current status of Dulaglutide in the United States: FDA approved. In sport: Not WADA prohibited. Details, sources, and the dated timeline follow.

By the PeptideAgent Editorial Team. Draft, pending editorial review.  Last verified

What is the current status of Dulaglutide?

Regulatory: FDA approvedWADA: Not WADA prohibitedVerified: Verified Sep 27, 2026
FDA and compounding
FDA approved product (Trulicity, September 2014; 3.0 mg and 4.5 mg doses added in 2020; pediatric indication in 2022; cardiovascular risk reduction indication based on REWIND). Because dulaglutide is a component of an approved drug, 503A pharmacies may compound it only for a documented patient specific need and may not produce essentially a copy of the commercial product. Dulaglutide is not available in a bulk powder form suitable for compounding. FDA listed dulaglutide injection as in shortage in its October 2024 to February 2025 GLP-1 updates, with all presentations available; it is not listed in FDA's shortage database as of September 27, 2026.
WADA
Not WADA prohibited
Access path
  1. Prescription from a licensed provider (in person or telehealth) filled at a retail pharmacy as Trulicity.
  2. Not available as a compounded product; dulaglutide is not on any FDA bulks list. FDA listed dulaglutide injection as in shortage, with all presentations available, in its October 2024 to February 2025 GLP-1 updates; it is not listed in FDA's shortage database as of September 27, 2026.
  3. Products labeled research use only are not lawful for human use.

Full Dulaglutide page: evidence, dosing in the literature, and sources

How has the status of Dulaglutide changed over time?

  1. FDA

    FDA approves Trulicity (dulaglutide) for type 2 diabetes

    FDA approved once-weekly dulaglutide injection (Trulicity) to improve glycemic control in adults with type 2 diabetes.

    Regulatory: FDA approvedSource: Drugs@FDA: Trulicity (dulaglutide) BLA 125469

Sources

Numbered citations in the answers above point here, followed by the regulatory sources on record for Dulaglutide and the source of each dated event.

  1. [1]FDA prescribing information for Trulicity (dulaglutide) injection, via DailyMedFDA, 2025
  2. [2]WADA Prohibited ListWADA, 2026
  3. [3]WADA 2027 Prohibited List (published September 21, 2026, in force January 1, 2027)WADA, 2026
  4. [4]FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize (GLP-1 shortage status updates, including liraglutide, and the April 1, 2026 policy update on essentially copies)FDA, 2026
  5. [5]FDA Drug Shortages database (dulaglutide not listed as of September 27, 2026)FDA, 2026
  6. [6]Drugs@FDA: Trulicity (dulaglutide) BLA 125469FDA, 2014